Immunology and Bi...
Follow
Find tag "#Remicade"
6.8K views | +16 today
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Anti-TNF therapy: past, present and future

Anti-TNF therapy: past, present and future | Immunology and Biotherapies | Scoop.it
Abstract

While for a century therapeutics has been dominated by small molecules, i.e. organic chemicals of ~400Da absorbable via the gut, this is no longer the case. There are now a plethora of important medicines which are proteins and injectable, which have dramatically improved the therapy of many inflammatory diseases and of cancer. Most of these are monoclonal antibodies, some are receptor Ig Fc fusion proteins, others are cytokines or enzymes. The key to this new aspect of therapeutics has been the filling of unmet needs, and the consequent commercial success, which promoted further research and development. The first ‘biologic’ for a common disease, rheumatoid arthritis (RA), was a monoclonal antibody, infliximab, to human tumour necrosis factor (TNF). This was based on our work, which is described in this review, summarizing how TNF was defined as a good target in RA, how it was developed is described here, as well as future indications for anti-TNF and related agents. Biologics are now the fastest growing sector of therapeutics.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 3, 12:52 PM
Claudia Monaco, Jagdeep Nanchahal, Peter Taylor, and Marc FeldmannAnti-TNF therapy: past, present and future

Int. Immunol. (2015) 27 (1): 55-62 doi:10.1093/intimm/dxu102

Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Best Selling Monoclonal Antibodies 2013

Best Selling Monoclonal Antibodies 2013 | Immunology and Biotherapies | Scoop.it

Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

impressive for immunologists so far away from so big amounts of money

more...
Krishan Maggon 's curator insight, January 6, 2014 8:38 AM

Abstract

 

A review of the best selling monoclonal antibodies in 2013 and 2012 is provided. Humira with sales of over $11 billion ($9.3 billion in 2012) remains the best selling monoclonal antibody, biologic as well prescription drug brand in 2013 as in 2012. The ranks of the next 4 top selling mabs remained unchanged from the 2012 Table.  Remicade (9.7 Bn), Rituxan (7.5 Bn) , Herceptin (6.5 Bn) and Avastin (6.5 Bn) were the second, third, fourth and fifth top selling mabs in 2013. The actual sales for 2013 as reported by the companies are provided. The total sales of the top selling blockbuster mabs were $63 billion in 2013. The actual global sales of all the approved blockbuster sales or potential (sales >1 billion) monoclonal antibodies in 2013 is provided. Besides the top 5 mabs, there were 2 other monoclonal antibodies with sales of over 2 billion dollars and 5 with sales of over $ 1 billion in 2013. In addition 5 recently launched mabs were nearing to reach sales of $ 1 billion this year. Currently 30 monoclonal antibodies are marketed in the US and Europe (January 2014).  Alexion Soliris was the most expansive marketed monoclonal antibody with a price tag of $440,000 per year of treatment, a sort of Rolls-Royce of mabs.

 

Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Physicochemical characterization of Remsima®

Physicochemical characterization of Remsima® | Immunology and Biotherapies | Scoop.it
(2014). Physicochemical characterization of Remsima®. mAbs: Vol. 6, No. 5, pp. 1163-1177. doi: 10.4161/mabs.32221

Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

first biosimilar

more...
Krishan Maggon 's curator insight, December 19, 2014 6:43 AM
mAbsVolume 6, Issue 5, 2014 Physicochemical characterization of Remsima® View full textDownload full textOpen accessDOI:10.4161/mabs.32221Soon Kwan Junga, Kyoung Hoon Leea, Jae Won Jeona, Joon Won Leea, Byoung Oh Kwona, Yeon Jung Kima, Jin Soo Baea, Dong-Il Kimb, Soo Young Leea & Shin Jae Changa*

pages 1163-1177

Publishing models and article dates explainedReceived: 30 Jun 2014Accepted: 30 Jul 2014Accepted author version posted online: 01 Nov 2014
Published online: 01 Sep 2014Article Views: 1197  http://www.celltrionhealthcare.com/remsima/com/